


134982

Translational Medicine Series 3



Lung Cancer

*Translational and
Emerging Therapies*

Edited by

Kishan J. Pandya

Julie R. Brahmer

Manuel Hidalgo

informa
healthcare

Contents

Preface iii

Contributors vii

- 1. Molecular Biology of Lung Cancer as the Basis for Targeted Therapy** 1
Oliver Gautschi, Philip C. Mack, Jim Heighway, Paul H. Gumerlock, and David R. Gandara
- 2. Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers** 25
Janet E. Dancey
- 3. Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors** 45
Nithya Ramnath and Alex A. Adjei
- 4. Antiangiogenic Therapy for Lung Cancer: Antibodies and Other Novel Agents** 73
Sarita Dubey and Ravi Salgia
- 5. Epidermal Growth Factor Receptor Inhibition in Non–Small Cell Lung Cancer** 81
Antonio Jimeno and Manuel Hidalgo
- 6. Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response** 97
Rafal Dziadziuszko, Barbara Szostakiewicz, and Fred R. Hirsch

- 7. Other Novel Targeted Therapies in Lung Cancer** 123
Kyriakos P. Papadopoulos and Anthony W. Tolcher
- 8. Lung Cancer Vaccines** 149
*Cheryl Ho, Oliver Gautschi, Primo N. Lara, David R. Gandara,
and Angela M. Davies*
- 9. Advances in Chemoradiation Treatment of Locoregionally
Advanced Non-Small Cell Lung Cancer** 175
Michael T. Milano and Yuhchyan Chen
- 10. Advances in the Treatment of Brain Metastases** 207
Malika L. Siker and Minesh P. Mehta
- 11. Recent Advances in Imaging for Lung Cancer** 231
Shweta Bhatt, Kristopher M. Skwarski, and Vikram S. Dogra